Stay updated on Aducanumab in Early Alzheimer's Clinical Trial
Sign up to get notified when there's something new on the Aducanumab in Early Alzheimer's Clinical Trial page.

Latest updates to the Aducanumab in Early Alzheimer's Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page now displays Biogen’s ClinicalTrials.gov record for the Phase 3 ENGAGE aducanumab study, including its study design, participant criteria, locations, and outcome measures. The record states that the trial was terminated following a futility analysis and that follow-up activities are complete.SummaryDifference100%

- Check14 days agoChange DetectedThe site footer revision changes from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check21 days agoChange DetectedA sitewide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to transition updates and FAQs.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2 while the page continued to show a 403 error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record details. This indicates access restrictions on the page rather than content updates.SummaryDifference17%

Stay in the know with updates to Aducanumab in Early Alzheimer's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Aducanumab in Early Alzheimer's Clinical Trial page.